Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Cyclerion Therapeutics (CYCN) over the last 6 years, with Q3 2025 value amounting to 0.4%.

  • Cyclerion Therapeutics' Return on Capital Employed rose 2700.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year increase of 2700.0%. This contributed to the annual value of 0.34% for FY2024, which is 6100.0% up from last year.
  • Latest data reveals that Cyclerion Therapeutics reported Return on Capital Employed of 0.4% as of Q3 2025, which was up 2700.0% from 0.43% recorded in Q2 2025.
  • Cyclerion Therapeutics' Return on Capital Employed's 5-year high stood at 0.4% during Q1 2025, with a 5-year trough of 4.07% in Q1 2023.
  • Over the past 5 years, Cyclerion Therapeutics' median Return on Capital Employed value was 1.15% (recorded in 2024), while the average stood at 1.44%.
  • In the last 5 years, Cyclerion Therapeutics' Return on Capital Employed plummeted by -28100bps in 2023 and then skyrocketed by 28200bps in 2024.
  • Cyclerion Therapeutics' Return on Capital Employed (Quarter) stood at 1.05% in 2021, then tumbled by -141bps to 2.54% in 2022, then soared by 38bps to 1.56% in 2023, then skyrocketed by 73bps to 0.43% in 2024, then grew by 5bps to 0.4% in 2025.
  • Its Return on Capital Employed stands at 0.4% for Q3 2025, versus 0.43% for Q2 2025 and 0.4% for Q1 2025.